Sanofi to acquire next-generation vaccine biotech Vicebio for US$1.6 billion
- Sanofi will gain access to Molecular Clamp technology that enables development of next-generation multivalent vaccines against respiratory pathogens and beyond
- Lead asset VXB-241 is a bivalent vaccine targeting Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV), currently in exploratory Phase 1
- Upfront payment of US$1.15 billion and milestones up to US$450 million
London, UK, 22 July 2025: Vicebio Ltd (“Vicebio” or the “Company”), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has entered an exclusive, definitive agreement to be acquired by Sanofi. Under the terms of the agreement, subject to customary conditions, Vicebio shareholders will receive up to a total of US$1.6 billion, including an upfront payment of US$1.15 billion as well as development and regulatory milestones payments of US$450 million.
